The University of Chicago Header Logo

Connection

Anjana Pillai to Carcinoma, Hepatocellular

Back to Details
This is a "connection" page, showing publications Anjana Pillai has written about Carcinoma, Hepatocellular.
Anjana Pillai
Connection Strength
13.233
Carcinoma, Hepatocellular
  1. The Changing Demographics and Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis. 2025 Feb; 29(1):1-15.
    View in: PubMed
    Score: 0.713
  2. Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
    View in: PubMed
    Score: 0.708
  3. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
    View in: PubMed
    Score: 0.693
  4. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.661
  5. Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy. Surg Oncol Clin N Am. 2024 01; 33(1):159-172.
    View in: PubMed
    Score: 0.654
  6. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int. 2023 02; 22(1):4-6.
    View in: PubMed
    Score: 0.615
  7. HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV. Dig Dis Sci. 2022 08; 67(8):3483-3484.
    View in: PubMed
    Score: 0.594
  8. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther. 2022 02; 55(4):479-480.
    View in: PubMed
    Score: 0.589
  9. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol. 2021 10; 19(10):2020-2024.
    View in: PubMed
    Score: 0.564
  10. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol. 2020 12; 115(12):1960-1969.
    View in: PubMed
    Score: 0.544
  11. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis. 2020 11; 24(4):681-700.
    View in: PubMed
    Score: 0.541
  12. Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 11; 115(11):1733-1736.
    View in: PubMed
    Score: 0.541
  13. Positron Emission Tomography With Computed Tomography as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma: Ready for Prime Time? Liver Transpl. 2020 06; 26(6):746-747.
    View in: PubMed
    Score: 0.522
  14. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 04; 64(4):985-992.
    View in: PubMed
    Score: 0.484
  15. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019 Mar; 13(2):125-137.
    View in: PubMed
    Score: 0.476
  16. Mixed Hepatocellular-Cholangiocarcinoma: Is It Time to Rethink Consideration for Liver Transplantation? Liver Transpl. 2018 10; 24(10):1329-1330.
    View in: PubMed
    Score: 0.468
  17. Influence of Acuity Circles on Hepatocellular Carcinoma and the Interaction of Gender and Race in Liver Transplantation. Clin Transplant. 2024 Dec; 38(12):e70045.
    View in: PubMed
    Score: 0.179
  18. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
    View in: PubMed
    Score: 0.176
  19. Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
    View in: PubMed
    Score: 0.171
  20. Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: A systematic review and meta-analysis. Liver Transpl. 2024 Jun 01; 30(6):595-606.
    View in: PubMed
    Score: 0.170
  21. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
    View in: PubMed
    Score: 0.169
  22. ACG Clinical Guideline: Focal Liver Lesions. Am J Gastroenterol. 2024 07 01; 119(7):1235-1271.
    View in: PubMed
    Score: 0.169
  23. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2024 Mar; 80(3):431-442.
    View in: PubMed
    Score: 0.167
  24. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.
    View in: PubMed
    Score: 0.163
  25. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
    View in: PubMed
    Score: 0.159
  26. Combined heart-liver transplantation practices survey in North America: Evaluation and organ listing practices. Liver Transpl. 2023 06 01; 29(6):591-597.
    View in: PubMed
    Score: 0.158
  27. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023 03; 43(3):695-707.
    View in: PubMed
    Score: 0.157
  28. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.154
  29. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.
    View in: PubMed
    Score: 0.152
  30. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.151
  31. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
    View in: PubMed
    Score: 0.150
  32. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
    View in: PubMed
    Score: 0.143
  33. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol. 2022 01; 20(1):204-215.e6.
    View in: PubMed
    Score: 0.138
  34. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.
    View in: PubMed
    Score: 0.137
  35. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193.
    View in: PubMed
    Score: 0.134
  36. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 02; 20(2):333-347.
    View in: PubMed
    Score: 0.127
  37. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
    View in: PubMed
    Score: 0.124
  38. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
    View in: PubMed
    Score: 0.124
  39. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
    View in: PubMed
    Score: 0.119
  40. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304.
    View in: PubMed
    Score: 0.100
  41. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
    View in: PubMed
    Score: 0.097
  42. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015 Jul; 30(7):1167-74.
    View in: PubMed
    Score: 0.093
  43. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr; 11(4):e1001624.
    View in: PubMed
    Score: 0.086
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.